Atlas Trials

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Clinical trial NCT03498716 · TERMINATED

Trial details

NCT number
NCT03498716
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2018-08-02
Primary completion
2023-08-14
Enrollment
2199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.